Resumen de Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience
Lucía Ceniceros Paredes, Ana Chopitea Ortega, Fernando Pardo Sánchez, Fernando Rotellar Sastre, Leire Arbea Moreno, Jesús J. Sola, José Carlos Súbtil, Bruno Sangro Gómez Acebo, Alberto Benito Boillos, José Luis Hernández Lizoain, Javier Rodríguez
Background Synchronous liver metastases (LM) from gastric (GC) or esophagogastric junction (EGJ) adenocarcinoma are a rare events. Several trials have evaluated the role of liver surgery in this setting, but the impact of preoperative therapy remains undetermined.
Methods Patients with synchronous LM from GC/EGJ adenocarcinoma who achieved disease control after induction chemotherapy (ICT) and were subsequently scheduled to chemoradiotherapy (CRT) to the primary tumor and surgery assessment were retrospectively analyzed. Pathological response, patterns of relapse, progression-free survival (PFS), and overall survival (OS) were calculated. From July 2002 to September 2012, 16 patients fulfilling the inclusion criteria were identified.
Results Primary tumor site was GC (nine patients) or EGJ (seven patients). LM were considered technically unresectable in nine patients. Radiological response to the whole neoadjuvant program was achieved in 13 patients. Eight patients underwent surgical resection of the primary tumor; in five of these LM were resected. A complete pathological response in the primary or in the LM was found in four and three patients, respectively. The most frequent site of relapse/progression was systemic (eight patients). Local and liver-only relapses were observed in two patients each. After a median follow-up of 91 months, the median OS and PFS were 23.0 (95% CI 13.2–32.8) and 17.0 months (95% CI 11.7–22.3). 5-year actuarial PFS is 17.6%.
Conclusion Our results suggest that an intensified approach using ICT followed by CRT in synchronous LM from GC/EGJ adenocarcinoma is feasible and may translate into prolonged survival times in selected patients.
